Document Classification

Section Type: METHODS

Text: The European Organisation for Research and Treatment of Cancer (EORTC) and Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Leukemia Groups conducted a randomized trial (AML-12 ; Combination Chemotherapy, Stem Cell Transplant and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia) in 1, 942 newly diagnosed patients with AML, age 15 to 60 years, comparing remission induction treatment containing daunorubicin, etoposide, and either standard-dose (SD) cytarabine (100 mg/m (2) per day by continuous infusion for 10 days) or high-dose (HD) cytarabine (3, 000 mg/m (2) every 12 hours by 3-hour infusion on days 1, 3, 5, and 7).